Market Closed -
Other stock markets
|
After market 07:14:38 pm | |||
733.5 USD | +1.19% | 734 | +0.07% |
Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
Financials (USD)
Sales 2024 * | 41.36B | Sales 2025 * | 51.28B | Capitalization | 661B |
---|---|---|---|---|---|
Net income 2024 * | 10.86B | Net income 2025 * | 15.78B | EV / Sales 2024 * | 16.3 x |
Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 13.1 x |
P/E ratio 2024 * |
60.5
x | P/E ratio 2025 * |
40.9
x | Employees | 43,000 |
Yield 2024 * |
0.71% | Yield 2025 * |
0.81% | Free-Float | 99.79% |
Latest transcript on Eli Lilly and Company
1 day | +0.07% | ||
1 week | +0.99% | ||
Current month | -5.71% | ||
1 month | -5.34% | ||
3 months | +14.75% | ||
6 months | +29.12% | ||
Current year | +25.83% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 18 M€ | +3.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 733.5 | +1.19% | 2,009,249 |
24-04-25 | 724.9 | -1.00% | 2,608,752 |
24-04-24 | 732.2 | -1.81% | 2,133,427 |
24-04-23 | 745.7 | +1.96% | 2,042,029 |
24-04-22 | 731.3 | +0.69% | 2,354,096 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B | |
-11.77% | 144B |
- Stock Market
- Equities
- LLY Stock